Vertex Pharmaceuticals Incorporated VRTX reported adjusted earnings of $3.98 per share for the fourth quarter of 2024, ...

Scotiabank raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $450 from $433 and keeps a Sector Perform rating on the shares.

HOUSTON, January 22, 2025--(BUSINESS WIRE)--Vertex Energy, Inc. ("Vertex" or the "Company"), a leading specialty refiner and marketer of high-quality refined products, together with its affiliates ...

The 2025 Formula 1 season promises to be one for the ... in Japan for round three at Suzuka on April 6. Bahrain and Jeddah form an Arabian doubleheader on the weekends of April 13 and 20.

Team India's struggles on the international circuit since the arrival of head coach Gautam Gambhir haven't gone down well with the board. The Board of Control for Cricket in India (BCCI) is ...

What's so special about Jan. 30 for Vertex? It's the PDUFA action date set by the U.S. Food and Drug Administration (FDA) for making an approval decision on suzetrigine in treating acute pain.

Along with its gene editing therapy Casgevy, Vertex is offering fertility preservation support for its patients—a program that the HHS claims violates anti-kickback statutes. In a court filing on ...

Former England captain Michael Vaughan expressed his frustration with the inconsistent batting form of Indian batter Shubman Gill while Australia's wicketkeeper-batting legend Adam Gilchrist had a ...

Next: Access Our New, Shockingly Simple 'Alert System' RBC Capital Markets says Vertex management is optimistic about the recently approved Alyftrek. They predict that most of the 6,000 patients ...

Vertex has been running a number of trials because if there’s one thing that we can take away from the failed drug development projects of the past, it’s that there are many kinds of pain.